ArticleMolecular therapy : the journal of the American Society of Gene Therapy2012
Delivery of siRNA to the mouse lung via a functionalized lipopolyamine.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 43 citations in OpenAlex.
- A Patent Analysis on Nano Drug Delivery Systems.Recent patents on nanotechnology · 2025Review
- Delivery of Anti-microRNA-712 to Inflamed Endothelial Cells Using Poly(β-amino ester) Nanoparticles Conjugated with VCAM-1 Targeting Peptide.Advanced healthcare materials · 2021Article
- Innovations in Biomaterial Design toward Successful RNA Interference Therapy for Cancer Treatment.Advanced healthcare materials · 2021Review
- Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects.Pharmaceutics · 2021Review
- Nanoparticle Delivery of Anti-inflammatory LNA Oligonucleotides Prevents Airway Inflammation in a HDM Model of Asthma.Molecular therapy. Nucleic acids · 2020Article
- Pulmonary Administration: Strengthening the Value of Therapeutic Proximity.Frontiers in medicine · 2020Review
- Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs.Molecular diagnosis & therapy · 2018Review
- Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines.Advanced drug delivery reviews · 2016Review
- A High-Throughput Method for Direct Detection of Therapeutic Oligonucleotide-Induced Gene Silencing In Vivo.Nucleic acid therapeutics · 2016Article
- Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension.Journal of controlled release : official journal of the Controlled Release Society · 2015Article
- Differential bioreactivity of neutral, cationic and anionic polystyrene nanoparticles with cells from the human alveolar compartment: robust response of alveolar type 1 epithelial cells.Particle and fibre toxicology · 2015Article
- Turning Squalene into Cationic Lipid Allows a Delivery of siRNA in Cultured Cells.Nucleic acid therapeutics · 2015Article
- Genetic and hypoxic alterations of the microRNA-210-ISCU1/2 axis promote iron-sulfur deficiency and pulmonary hypertension.EMBO molecular medicine · 2015Article
- Epigenetic targets for novel therapies of lung diseases.Pharmacology & therapeutics · 2015Review
- In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight.Nature nanotechnology · 2014Article
- siRNA delivery to the lung: what's new?Advanced drug delivery reviews · 2014Review
- Delivery of therapeutic siRNA to the lung endothelium via novel Lipoplex formulation DACC.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Development of a Positive-readout Mouse Model of siRNA Pharmacodynamics.Molecular therapy. Nucleic acids · 2013Article
- Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Progress toward in vivo use of siRNAs-II.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have designed a series of versatile lipopolyamines which are amenable to chemical modification for in vivo delivery of small interfering RNA (siRNA). This report focuses on one such lipopolyamine (Staramine), its functionalized derivatives and the lipid nanocomplexes it forms with siRNA. Intravenous (i.v.) administration of Staramine/siRNA nanocomplexes modified with methoxypolyethylene glycol (mPEG) provides safe and effective delivery of siRNA and significant target gene knockdown in the lungs of normal mice, with much lower knockdown in liver, spleen, and kidney. Although siRNA delivered via Staramine is initially distributed across all these organs, the observed clearance rate from the lung tissue is considerably slower than in other tissues resulting in prolonged siRNA accumulation on the timescale of RNA interference (RNAi)-mediated transcript depletion. Complete blood count (CBC) analysis, serum chemistry analysis, and histopathology results are all consistent with minimal toxicity. An in vivo screen of mPEG modified Staramine nanocomplexes-containing siRNAs targeting lung cell-specific marker proteins reveal exclusive transfection of endothelial cells. Safe and effective delivery of siRNA to the lung with chemically versatile lipopolyamine systems provides opportunities for investigation of pulmonary cell function in vivo as well as potential treatments of pulmonary disease with RNAi-based therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.